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Vitamin D deﬁciency is widely prevalent across all ages, races, geographical regions, and socioeconomic strata. In addition to
its important role in skeletal development and calcium homeostasis, several recent studies suggest its association with diabetes,
hypertension, cardiovascular disease, certain types of malignancy, and immunologic dysfunction. Here, we review the current
evidence regarding an association between vitamin D deﬁciency and hypertension in clinical and epidemiological studies. We
also look into plausible biological explanations for such an association with the renin-angiotensin-aldosterone system and insulin
resistance playing potential roles. Taken together, it appears that more studies in more homogeneous study populations are needed
beforeaﬁrmconclusioncanbereachedastowhethervitaminDdeﬁciencycausesoraggravateshypertensionandwhethervitamin
D supplementation is safe and exerts cardioprotective eﬀects. The potential problems with bias and confounding factors present
in previous epidemiological studies may be overcome or minimized by well designed randomized controlled trials in the future.
1.Introduction
Vitamin D deﬁciency has been described worldwide [1].
In addition to its important role in skeletal development
and calcium homeostasis, it has been suggested that low
vitamin D nutritional status may have an impact on extra-
skeletal health including increased risk of certain types
of malignancy, immunologic dysfunction, diabetes, and
cardiovascular disease [2, 3]. The socioeconomic burden
of the above chronic diseases that have been linked to
vitamin D deﬁciency is enormous. The estimated yearly
total health costs for persons in the United States with
heart disease and hypertension was 148 billion US dollars in
1996 [4]. Since both hypertension and vitamin D deﬁciency
are highly prevalent worldwide, establishing an association
among these two may potentially have wide public health
implications butmayalsobetheresultofthehighprevalence
ofbothconditionsratherthanacausativelinkbetweenthem.
Given the low cost and low side eﬀect proﬁle of vitamin D,
replacing it in vitamin D deﬁcient populations may help
reduce the burden of this condition and simultaneously
reduce cardiovascular risk.
2.Biological Roles ofVitaminDinHumans
There are two main sources of vitamin D available to
humans, from direct exposure to sunlight (Solar UV-B) and
from the diet or dietary supplements. Solar UV-B radiation
penetrates the skin and converts 7-dehydrocholesterol to
previtamin D3, which, in turn, converts rapidly to vitamin
D3. The oily ﬁshes such as salmon, sardines, and mackerel,
egg yolks, and ﬁsh oils such as cod liver oil contain vitamin
D naturally. Fortiﬁed milk, cereal, juice, and yogurt are
dietary sources in North America. The cutaneous synthesis
o fv i t a m i nDm a yv a r yw i d e l yi nd i ﬀerent populations
depending on their availability of sun exposure as well
as the actual sun exposure of the bare skin when the
sun light is available. Skin pigmentation with melanin is2 International Journal of Endocrinology
a limiting factor in the cutaneous synthesis of vitamin D.
Melanin acts as an eﬀective natural sunscreen and, therefore,
increased skin pigment can greatly reduce the solar UV-B-
mediated cutaneous synthesis of vitamin D3 by as much as
99% [5].
Vitamin D from the skin and diet is metabolized
in the liver to 25-hydroxyvitamin D[25(OH)D]. This
25(OH)D is metabolized in the kidneys by the enzyme 25-
hydroxyvitamin D-1α-hydroxylase (CYP27B1) to its active
form, 1,25-dihydroxyvitamin D[1,25(OH)2D]. The renal
production of 1,25(OH)2D is closely regulated by serum
p a r a t h y r o i dh o r m o n e( P T H )l e v e l sa sw e l la sb ys e r u m
calcium and phosphorus levels [6]. The absorption of renal
calcium as well as intestinal calcium and phosphorus is
increased in the presence of 1,25(OH)2D[ 7].
The 1,25(OH)2D ligand binds to the vitamin D receptor
(VDR) and triggers an increase in intestinal absorption of
both calcium and phosphorus. Vitamin D is also involved
in bone formation, resorption, and mineralization as well
as in maintaining neuromuscular function. Circulating
1,25(OH)2D reduces the serum PTH level directly by
decreasing parathyroid gland activity and indirectly by
increasing serum calcium. It also regulates bone metabolism
in part by interacting with the VDR in osteoblasts to release
biochemical signals, leading to formation of mature osteo-
clasts. The osteoclasts release collagenases and hydrochloric
acid to dissolve the matrix and mineral, releasing calcium
into the blood [8].
Decreasing vitamin D levels impairs the calcium and
phosphorus homeostasis in the body. Vitamin D is primarily
responsible for regulating the eﬃciency of intestinal cal-
cium absorption. Its deﬁciency decreases the absorption of
calcium from the small intestine. This leads to a cascade
of events by increasing the production and release of PTH
into the circulation, which restores calcium homeostasis by
increasing tubular reabsorption of calcium in the kidney,
increasing bone calcium mobilization from the bone, and
enhancing the production of 1,25(OH)2D[ 8].
Even though the bone, small intestine, and kidneys are
the primary organs responsive to vitamin D, the eﬀects of
vitamin D in the body are more far reaching. The vitamin
D receptor (VDR) has been identiﬁed in many cell types,
tissues, and organs, including those not typically associated
with calcium homeostasis and bone metabolism indicating
that vitamin D may also be involved in important biological
processes beyond calcium homeostasis [9]. Some of these
include the heart, vascular smooth muscle, endothelium,
stomach, pancreas, brain, skin, gonads, and various cells
of the immune system [8]. VDR is a steroid hormone
nuclear receptor that binds to 1,25(OH)2D with high
aﬃnity and mediates transcriptional gene regulation [8].
Recent evidence suggests that the VDR is also involved
in mediating noncalcemic eﬀects of vitamin D and its
analogues and may play a vital role in disease prevention
andmaintenanceofextra-skeletalhealth.Anumberofrecent
studies involving cell culture and VDR knockout mice have
suggested that vitamin D plays a critical role in regulating
the Renin-Angiotensin System (RAS) and thus inﬂuencing
the regulation of blood pressure [10, 11].
3. Observations of Racialand
GeographicalFactorsInﬂuencing
VitaminDNutritionalStatus
There are various cultural, social, racial, and geographical
factors that may inﬂuence the inadequacy of vitamin D.
Degree of exposure of bare skin to the sunlight is an
important factor in determining vitamin D status. A change
in season or latitude may have a dramatic eﬀect on the
cutaneous production of cholecalciferol. In the INTERSALT
study, which examined >10 000 participants from around
the world, the systolic and diastolic blood pressure were
signiﬁcantly and positively associated with distance from
the equator [12, 13] .I nE d m o n t o n ,C a n a d a( 5 2 ◦ N), the
photosynthesis of precholecalciferol essentially ceases by
mid-October and does not resume until mid-April, thus
inﬂuencing the vitamin D concentration in that population
[14]. Covering the entire body with clothing (as customary
in women in some religions), use of sunscreen and glass
shielding may signiﬁcantly reduce or completely eliminate
the production of vitamin D3 in the skin [15]. Biological
factors that inhibit cutaneous vitamin D synthesis and bio-
availability include skin pigmentation, medication use, body
fat content, fat malabsorption, and age [16]. Increased skin
pigmentation can reduce cutaneous vitamin D3 production
as much as 99.9%, which may explain, at least in part, the
higher prevalence of vitamin D deﬁciency in the African
American population [5]. In addition, ethnic-speciﬁc poly-
morphisms of the vitamin D receptor gene and its promoter
mayinﬂuencevitaminDactionincludingindividualcalcium
absorption.
4. Epidemiological Evidence of the Relationship
between Vitamin D and Hypertension
Several clinical and epidemiological studies have shown
that there may be an association between hypertension and
vitamin D status as well as calcium metabolism. In 1980,
McCarron et al. [17] postulated that disorders of calcium
metabolism including hyperparathyroidism may be related
todevelopmentofhypertensionandshowedinhisstudythat
hypertensive patients had a signiﬁcant (P<. 005) relative
hypercalciuriawhencomparedtonormotensives.Intheearly
1990s, Cooper and Rotimi observed geographic diﬀerences
in blood pressure among individuals of African origin. He
found that those residing in the northern regions had higher
blood pressure than those residing closer to the equator [18].
Langford and Watson [19] noted that children from rural
Mississippihadhigherbloodpressureandlowcalciumintake
compared to urban children. Zemel et al. [20, 21]f o u n d
that the intake of calcium in salt-sensitive blacks can reduce
blood pressure and cause partial regression of left ventricular
hypertrophy. Other investigators have found similar results
[22, 23].
Scragg et al. [24] recently reported their ﬁndings of
the relationship between serum 25(OH)D concentration
and blood pressure. The authors studied the data from the
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(NHANES III), a nationally representative cross-sectional
survey of the noninstitutionalized population in the United
States carried out during 1988–1994. A signicant inverse
association was reported between serum 25(OH)D con-
centration and blood pressure that was evident even after
adjustment for variables including age, gender, ethnicity, and
physical activity. After dividing the subjects into 25(OH)D
quintile groups, the authors found that the mean systolic
blood pressure was 3.0mmHg lower and the diastolic blood
pressure was 1.6mm Hg lower in the highest quintile [serum
25(OH)D ≥85.7nmol/L],comparedwiththelowestquintile
[serum 25(OH)D ≤ 40nmol/L] of vitamin D status. The
mean diﬀerence in systolic BP was higher among non-
Hispanic blacks than Mexican Americans compared to
non-Hispanic whites, after adjusting for age and sex. This
diﬀerence in systolic BP in non-Hispanic blacks (compared
to non-Hispanic whites) becomes blunted when quintile of
vitamin D is added to the model, indicating that higher
prevalence of vitamin D deﬁciency in non-Hispanic blacks
has contributed to the higher mean systolic BP in this group
of population.
Judd et al. [25] also analyzed the NHANES III survey
data and showed a statistically signiﬁcant inverse association
between circulating 25(OH)D concentrations and systolic
bloodpressure.However,thisassociationwasnotstatistically
signiﬁcant when age was included in the model, nor was it
signiﬁcant in the black subpopulation.
Martins et al. [26] found that a low vitamin D level was
associated with a higher risk of having hypertension. This
cross-sectional study, using the NHANES III data, looked
at the association between serum 25(OH)D and several
cardiovascular disease risk factors, including hypertension,
in the adult US population. The 25(OH)D levels were
found to be signiﬁcantly lower in women, elderly persons
(≥60 years), racial/ethnic minorities, and participants with
obesity, hypertension, and diabetes mellitus. The adjusted
prevalence of hypertension in adults in the US was 30%
higherinthelowestquartilecomparedtothehighestquartile
of serum 25(OH)D.
In summary, the NHANES III data analyses showed
an inverse association between blood pressure and vitamin
D concentration, even though it is not consistent across
all diﬀerent groups of subpopulations in the above three
analyses. This is most likely due to the diﬀerences in
the variable adjusted and the samples included in the
analyses.
Forman et al. [27] prospectively investigated the inde-
pendent association between plasma 25(OH)D levels and
riskofincidenthypertension.Twoprospectivecohortstudies
that included 613 men from the Health Professionals’
Follow-Up Study and 1 198 women from the Nurses’ Health
Study with measured 25(OH)D levels were followed for 4 to
8 years. After this follow-up, the multivariable relative risk
(RR) of incident hypertension among those whose measured
plasma 25(OH)D levels were <15ng/mL (compared with
those whose levels were >3 0 n g / m L )w a s6 . 1 3i nm e na n d
2.67inwomen.Theseﬁndingsprovidesupportinfavorofan
association between vitamin D deﬁciency and the increased
risk of hypertension.
5. Clinical Studies Showing Effect of Vitamin D
Supplementation on Blood Pressure
Increasing vitamin D level in the blood directly or indirectly
has been shown to reduce blood pressure in some studies.
Krause et al. randomly assigned 18 patients with mild
hypertension to receive UV-B or UV-A exposure, 3 times
weekly for 6 weeks [28]. In this study, he found that there
wasa162%riseinplasma25(OH)DintheUV-Bgroupalong
with a drop in both systolic and diastolic blood pressure by
6mm Hg. No change in the blood pressure was observed
with UV-A exposure (UV-A does not produce vitamin D). In
another randomized, placebo-controlled study in 145 elderly
women showed that 800IU of vitamin D3 plus 1200mg of
calcium signiﬁcantly reduced blood pressure by 9.3% after
8weeks, whereas treatment with 1200mg of calcium alone
reduced blood pressure by only 4.0% (P = .02) [29].
6. Epidemiological StudiesShowing
No Relationship betweenVitaminD
and Hypertension
Even though the majority of recent clinical studies cited
earlier in this review support the hypothesis of an inverse
association between the vitamin D serum level and blood
pressure, there have been studies that contradict this hypoth-
esisaswell.Forinstance,alargeprospectivestudybyForman
et al. in 2005 found no association between vitamin D
intake from diet and supplements and the risk of incident
hypertension [30].
In the Women’s Health Initiative Calcium/Vitamin D
Trial by Margolis et al. supplementation of 1000mg of
elemental calcium plus 400IU of vitamin D3 daily (versus
placebo) in a random double-blind fashion did not show any
signiﬁcant decrease in incidence hypertension after a median
followup time of 7 years [31]. In another longitudinal,
placebo-controlled, double-blind study by Orwoll Oviatt,
normotensive men were treated with a calcium and chole-
calciferol supplement, or placebo, for 3 years without any
demonstrable eﬀect on systolic, diastolic, or mean arterial
pressure [32]. The randomized double-blind trial by Scragg
et al. with a vitamin D supplementation at a single dose
of 2.5mg in winter months did not show any signiﬁcant
decrease in blood pressure after 5 weeks when compared
to placebo [33]. Snijder et al. studied the participants of
the Longitudinal Aging Study in Amsterdam and found
that blood pressure in this population was not inversely
associated with the serum 25(OH)D level but was positively
correlated with serum PTH [34]. Another study conducted
in Germany showed similar ﬁndings [35].
7. Possible Cause/Explanationfor
Lackof an Association between the
VitaminDLevel andBlood Pressure
The reasons behind these contradictory ﬁndings in the above
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and vitamin D could be multiple. The earlier observational
study by Forman did not have information about the exact
amount of vitamin D intake and it was estimated from
a semiquantitative food frequency questionnaire [30]. The
diagnosis of hypertension was also only self-reported in
this study, not by direct measurement of the participant’s
blood pressure. Unless the subjects with lower intake of
vitamin D had clinically signiﬁcant deﬁciency, an association
between vitamin D status and blood pressure is likely to be
missed. If vitamin D decreased blood pressure mainly via
inhibiting the RAS, we may not see any decrease in blood
pressure if the subjects do not have a vitamin D level below a
certain threshold, at which a hyperreninemic state is created.
Thus, vitamin D supplementation would also be unlikely
to produce any decrease in blood pressure in normotensive
subjects as their plasma renin is likely to be normal. The
study by Scragg et al. measured blood pressure response only
after 5 weeks of vitamin D intake which may be too early
to show any clinical response [33]. In the study by Snijder
et al., the authors postulated that the lack of an association
between blood pressure and vitamin D level may be due to
the relatively high levels of vitamin D in that population
[34].
T h em o r er e c e n tra n d o m i z e dc o n tr o ll e dtri a lb yM a r g o l i s
et al. [31] was a substudy of the Women’s Health Initiative
(WHI) that was originally designed to look at hip fractures
and colorectal cancers. In an editorial comment about this
study, Geleijnse mentioned that there may be several ﬂaws in
thisstudy[36].ThelevelofcompliancetovitaminD/calcium
was only modest (60% women reported taking >80% study
medications); BP measurement criteria were not strict at
the site visit and were probably not blinded to staﬀ and
participants. Nearly half of the participants were already
hypertensive at baseline and 28% used antihypertensive
medications. Incident hypertension was self reported, based
on asking women twice per year if they had been started
on new “pills for hypertension.” The vitamin D dose used
in the study (400IU) was fairly low, and the estimated
increase of the vitamin D level with this supplementation
in this study population was about 2ng/mL (5nmol/L)
[37] which may be too low to produce any clinical eﬀect
on blood pressure. In the study by Judd et al., [25] the
authors suspected that using a 25(OH)D cutoﬀ point of
<80nmol/L to deﬁne vitamin D insuﬃciency had placed the
majority of blacks (92%) into the vitamin deﬁcient group,
leaving too few people in the nondeﬁcient group, resulting
in failure to detect a statistically signiﬁcant association
between hypertension and vitamin D. The inverse associa-
tion between blood pressure and 25(OH)D concentration
was further weakened after controlling for age because
vitamin D production decreases in older adults secondary
to lower skin concentrations of 7-dehydrocholesterol (the
precursor to D3). Increasing age is also associated with
decreased concentrations of 25(OH)D [38]. Since these
two variables are highly correlated, adjusting for one (age,
in this case) had weakened the association of the other
variable (vitamin D level) with systolic blood pressure in this
study.
8. Evidence of a Relationship between
VitaminDandPreeclampsia
Maternal vitamin D deﬁciency is a widespread public health
problem. In a recent study, it was found that approximately
29% of black pregnant women and 5% of white pregnant
women residing in the northeastern United States had
vitamin D deﬁciency (25(OH)D < 37.5nmol/L), whereas
54% of black women and 47% of white women had vitamin
D insuﬃciency with a serum 25(OH)D levels of 37.5–80
nmol/L [39]. Preeclampsia is a pregnancy-speciﬁc syndrome
that aﬀects approximately 3%–7% of ﬁrst pregnancies. The
known racial disparity in preeclampsia, with black women
being more likely to develop severe preeclampsia and suﬀer
greater morbidity associated with the disorder than white
women [40], is consistent with the hypothesis that vitamin
D deﬁciency may be involved in the development of this
condition.
Hypp¨ onenetal.[41]investigatedtheassociationbetween
infant vitamin D supplementation and development of
preeclampsia in those persons later in life when they
become pregnant. The investigators used data on 2 969
women born in the Northern Finland Birth Cohort 1966
of whom 68 (2.3%) had preeclampsia in their ﬁrst preg-
nancy. Risk of preeclampsia was halved ((OR) 0.49, 95%
CI 0.26–0.92) in participants who had received vitamin
D supplementation regularly during the ﬁrst year of life.
Studies of seasonal patterns in preeclampsia showed that
the incidence of preeclampsia was the lowest in summer,
when sunlight is plentiful and serum 25(OH)D concen-
trations are at their peak, and the highest in winter,
when synthesis of vitamin D3 is limited in temperate
zones and serum 25(OH)D levels are at their nadir [42,
43]. In a nested case-control study by Bodnar et al.
[44], pregnant women were followed from less than 16-
week gestation to delivery at prenatal clinics and private
practices. Patients included nulliparous pregnant women
with singleton pregnancies only. Adjusted serum 25(OH)D
concentrations in early pregnancy were 15% lower in
womenwhosubsequentlydevelopedpreeclampsiacompared
to controls. Early-pregnancy maternal 25(OH)D concen-
tration less than 37.5nmol/L was associated with a 5-
fold increase in the odds of preeclampsia, independent of
race/ethnicity, season, gestational age, prepregnancy BMI,
and education. After confounder adjustment, a 50-nmol/L
decline in 25(OH)D concentration doubled the risk of
preeclampsia. Findings of this study indicate that maternal
vitamin D deﬁciency may be an independent risk factor for
preeclampsia.
Very recently, Bills et al. reported that low plasma
vascular endothelial growth factor (VEGF) in the ﬁrst
trimester is a predictive marker for preeclampsia [45]. On
the other hand, Cardus et al. found that 1,25 (OH)2 vitamin
D regulates VEGF production through a vitamin D response
element in the VEGF promoter [46]. Thus, lack of vitamin D
may have a role in pathogenesis of developing hypertension
via decreased VEGF production.International Journal of Endocrinology 5
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Figure 1: Pathway of vitamin D metabolism and its relationship with PTH and renin-angiotensin-aldosterone system.
9. Vitamin DDeﬁciency and Hypertension:
PotentialBiologicalMechanisms
9.1. Regulation of the Renin Angiotensin System (RAS). The
renin angiotensin system (RAS) is a regulatory cascade that
plays a critical role in the regulation of blood pressure,
electrolyte, and plasma volume homeostasis. Inappropriate
stimulation of the RAS has been associated with hyper-
tension. Li et al. [10] demonstrated that vitamin D is a
potentendocrinesuppressorofreninbiosynthesistoregulate
the RAS. Mice lacking vitamin D receptor (VDR) have
elevated production of renin and angiotensin II, leading
to hypertension, cardiac hypertrophy, and increased water
intake. These abnormalities can be prevented by treatment
with an ACE inhibitor or AT1 receptor antagonist. Vitamin
D suppression of renin expression is independent of calcium
metabolism, the volume and salt-sensing mechanisms, and
the angiotensin II feedback regulation. In normal mice, vita-
min D deﬁciency stimulates renin expression, whereas injec-
tion of 1,25-dihydroxyvitamin D3[1,25(OH)2D3]r e d u c e s
renin synthesis. In cell cultures, 1,25(OH)2D directly sup-
presses renin gene transcription by a VDR-dependent mech-
anism. Thus, vitamin D-deﬁciency may increase the risk
of hypertension, and vitamin D supplementation may be
beneﬁcialtothecardiovascularsystem.Inatransgenicmouse
model with mice over-expressing the human vitamin D
receptor in renin-producing cells, Kong et al. demonstrated
that suppression of renin expression by 1,25(OH)2 Di nv i v o
is independent of parathyroid hormone and calcium [47]
(see Figure 1).
9.2. Relationship of Parathyroid Hormone with Hypertension
in Primary and Secondary Hyperparathyroidism. Vitamin
D deﬁciency is prevalent in patients with primary hyper-
parathyroidism (HPT) [48–50]. Primary HPT with an
inappropriately elevated PTH level has been shown to be
associated with hypertension (in up to 40% of cases) but
the mechanism of developing hypertension has remained
controversial. Low vitamin D status is associated with
secondary elevation of PTH as well as increased arterial
resistance leading to hypertension [51]. It has also been
implicateddirectlyandindirectlytoaﬀectcardiovascularrisk
by increasing susceptibility to arterial calciﬁcation [52]. The
patients with mild primary HPT have been found to have
increased stiﬀness measured in the radial artery [53]. In both
primary and secondary hyperparathyroidism, elevated PTH
levels may contribute to elevation of blood pressure.
Puepet et al. [54] reported a 47-year-old Nigerian
man with severe hypertension (BP 210/130mmHg) and
primary hyperparathyroidism who had a normal blood
pressure after parathyroidectomy. Gennari et al. [55] studied
patientswithprimaryhyperparathyroidismwithparathyroid
adenoma and observed that plasma renin activity, and
plasma aldosterone levels were higher among these patients
who were hypertensive and the blood pressure, plasma
renin activity and plasma aldosterone levels became normal6 International Journal of Endocrinology
after parathyroidectomy in most of them. These results
are consistent with the hypothesis of a possible direct
eﬀect of PTH on renin secretion, which could contribute
to the pathogenesis of hypertension. However, there are
contradictory results as well. Bollerslev et al. studied the
eﬀect of parathyroidectomy on cardiovascular risk factors in
patients with mild primary hyperparathyroidism and found
no signiﬁcant diﬀerences between the groups for blood
pressure or markers of insulin resistance [56]. On the other
hand, Rydberg et al. [57] found increased blood pressure
values after parathyroidectomy in patients with primary
hyperparathyroidism and a history of hypertension. Jorde et
al. found that serum PTH was a signiﬁcant predictor of rise
in systolic blood pressure over a period of 7 years in men
(P<. 01), but not in women [58]. Fardella and Rodriguez-
Portales observed a positive correlation between PTH and
intracellular calcium and suggested that PTH may act as an
ionophore for calcium entry into cells and perhaps react
a prehypertensive condition in normotensive patients with
primary hyperparathyroidism [59].
9.3. Vitamin D Deﬁciency, Obesity, and Insulin Resistance.
An association of obesity with low serum vitamin D levels
has been reported. Physical inactivity including decreased
outdoor activities may lead to diminished exposure to
ultraviolet light. This may partly account for the lower level
of serum vitamin D in overweight and obese participants,
who are more likely to be sedentary in their lifestyle.
Analyzing the NHANES III data, Scragg and Camargo Jr.
reported a 25 percent reduction in the prevalence in the
vitamin D deﬁciency among the study population who
had increased outdoor physical activities in the previous
month prior to data collection [60]. In addition, the lipid
solubility of vitamin D also modiﬁes its bioavailability due
to sequestration in the adipose tissue and may contribute to
the lower serum levels of vitamin D in overweight and obese
persons [61]. There are some observational and case-control
studies suggesting that hypovitaminosis D is associated
with decreased insulin secretion [62] and that vitamin D
supplementation reduces the concentrations of free fatty
acids in diabetics, thereby improving insulin sensitivity [63].
There is a high prevalence of type 2 diabetes and insulin
resistance in patients with primary hyperparathyroidism
which could aggravate hypertension and inﬂammation, fur-
ther contributing to the cardiovascular risk in these patients
[64, 65]. In a prospective study by Ahlstr¨ om, PTH correlated
with several metabolic factors within a normocalcemic study
population and individuals with mild primary HPT had
signiﬁcantlymoreNCEP criteriaforthemetabolic syndrome
[66].
Scraggetal.reportedhypovitaminosisDbeingassociated
with higher insulin resistance and increased risk of diabetes
[67, 68]. Pittas et al. prospectively evaluated the eﬀect of
vitamin D supplementation (400IU per day) on fasting glu-
cose which improved after a 3-year period of therapy when
compared to subjects on placebo [69]. In a Framingham
Oﬀspring study involving nondiabetic individuals, a strong
inverse correlation between serum vitamin D concentrations
andfastingplasmaglucoseaswellasfastinginsulinlevelswas
found, after adjustment for age, gender, BMI, waist circum-
ference, and smoking [70]. In another cross-sectional study
involving hemodialysis patients [71], low serum vitamin D
was independently associated with diabetes mellitus, higher
brain natriuretic peptide levels, higher pulse pressure, and
higher vascular calciﬁcation scores.
Resnick and colleagues espouse an “ionic”-based theory
for the onset and development of hypertension, type 2 dia-
betes,obesity,andothermanifestationsofthemetabolicsyn-
drome that is characterized by elevated intracellular calcium,
reduced intracellular magnesium, and reduced intracellular
pH [72–76]. Intracellular calcium appears to have a biphasic
eﬀect on the diﬀerentiation of preadipocytes to adipocytes.
Low serum calcium resulting from low dietary intake or vita-
min D deﬁciency leads to secondary elevation of PTH which,
in turn, causes increased intracellular calcium [77] that leads
to increased diﬀerentiation of preadipocytes to adipocytes
[78]. It also inhibits GLUT-4 function impeding insulin
mediated glucose uptake [79]. On the other hand, increased
dietary calcium appears to be associated with inhibition of
serum 1,25 hydroxy vitamin D which results in decreased
intracellular calcium levels and thus decreased adipogenesis
[80, 81]. There is also accumulating evidence suggesting
that increased intracellular calcium has stimulating eﬀect
on adipocyte 11-beta hydroxysteroid dehydrogenase (HSD)
type 1 activity similar to angiotensin 2, leading to increased
cortisol production in adipocytes [82]. Among other means,
this appears to be a membrane-mediated (rather than
nuclear receptor mediated) eﬀect of 1,25 hydroxy vitamin D
which can be inhibited by an angiotensin receptor blocker
(see Figures 2(a), 2(b)).
9.4. Vitamin D Deﬁciency, Calcium, and Endothelial Function.
Hypovitaminosis D has been shown to have direct eﬀects
on the vasculature causing increased vascular resistance [83].
It is also independently associated with increased carotid
intima-media thickness [84] and decreased arterial compli-
ance [85]. Sugden et al. found that endothelial function
(as assessed by ﬂow-mediated dilation) and blood pressure
improved in diabetics who ingested a single dose of vitamin
D (100 000IU) [86]. Ekmekci et al. [87] reported that
elevatedserumcalciumandparathyroidhormonelevelswere
independentpredictorsofimpairedendothelialfunctionand
endothelial nitric oxide polymorphism (eNOS), which is
often associated with coronary artery disease, and hyper-
tension, did not appear to have modifying eﬀect on the
endothelial function in his study.
10. Conclusions
Evidence from clinical and epidemiological studies support
a possible relationship between low vitamin D level and
hypertension, and there are some plausible biological mech-
anisms as well. However, epidemiological studies are always
vulnerable to multiple confounding factors that cannot be
always controlled. The unique and complex interactions
between hypovitaminosis D, parathyroid hormone, and cal-
cium (both in the serum and in intracellular compartments)International Journal of Endocrinology 7
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make it especially diﬃcult to tease apart how much of these
eﬀects are truly unique and distinct to vitamin D. Moreover,
statistically signiﬁcant associations between two factors do
not prove that one has been the causative factor for the
other, as these two factors may be closely related to a third
factor. In this case, a low vitamin D level may merely be a
surrogate for the lack of outdoor physical activity. Outdoor
physical inactivity itself may precipitate hypertension as well
as leading to a cascade of events (including low sun-exposure
and vitamin D deﬁciency, obesity, metabolic syndrome,
and increased insulin resistance), all of which may cause
or aggravate hypertension. The problems with bias and
confounding factors may be overcome or minimized by well-
designed randomized controlled trials.
Results of recent interventional studies that investigated
the potential beneﬁt of vitamin D supplementation on blood
pressurehavenotbeenpromising.Furtherstudiesareneeded
toﬁndoutifandwhenvitaminDsupplementationshouldbe
used for treating patients with hypertension. It is apparent
that vitamin D supplementation may be appropriate for
populations that are most vulnerable to hypovitaminosis D.
B u ti ti sn o tc l e a rw h a td e g r e eo fv i t a m i nDd e ﬁ c i e n c ym a y
activate the renin-angiotensin system (RAS) and trigger an
increase in blood pressure. Most recent studies investigating
the association of health conditions related to vitamin D
suggest that a desirable 25(OH)D concentration may be at
least 30ng/mL (75nmol/L) (but less than 100ng/mL) for
optimumhealth;yetnoconsensushasbeenreachedaboutits
cut-oﬀlevel[88–90].Thisalreadyrepresentsalimitingfactor
in future studies, as each individual likely has a diﬀerent
cut-oﬀ, depending on ethnic group and/or polymorphisms
in the vitamin D receptor and its promoter which mediates
vitamin D action. Therefore, more comprehensive studies
may be needed including genetic proﬁling of study subjects
withvariouslevelsofserumvitaminDtoseewhatisthemost
likely cutoﬀ level that triggers clinical hypertension. The
challenge remains that hypertension is multifactorial and
some individuals with other comorbidities (like smoking,
obesity, physical inactivity, metabolic syndrome) may have
a lower threshold for vitamin D deﬁciency induced clinical
hypertension compared to those who donot have these risk
factors.
Because of the increasing evidence in favor of an
association between vitamin D deﬁciency and cardiovas-
cular diseases, it may be prudent to screen and correct
hypovitaminosis D in high-risk patients such as those
with resistant hypertension, nursing home residents, osteo-
porotic individuals, pregnant women in areas where the
incidence of toxemia of pregnancy is high (south-east Asia),
African Americans, and the female population in some
geographic/religious groups where covering the entire body
with clothing is customary. If screening is not available,
supplementation with vitamin D 1000–2000IU daily among
this subpopulation may be safe and appropriate [91–93].
This can easily be achieved as vitamin D is available over
the counter and is unlikely to cause any toxicity at this
dosage. Finally, studies are underway to ﬁnd vitamin D
analogs with minimal calcemic potential but greater activity
on RAS modulation. This may open a new horizon for
a group of therapeutic inhibitors of the RAS and potentially
oﬀer a new class of antihypertensive drugs that may be
used in hypertensive individuals with or without vitamin D
deﬁciency.
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